Weekly Briefing Low Evidence

GLP-1 Medicines and Alcohol Use: What Trials Actually Tested

A dated correction separating rodent findings, three published semaglutide trials, and a completed registry entry without posted results.

PepCodex Research Team
6 min read
#glp-1 #semaglutide #alcohol #addiction #neuroscience

Correction, 29 September 2026: An earlier version described a single new study combining receptor-knockout experiments in mice with brain imaging of people taking semaglutide. It also attributed a statement about this work to the National Institute on Alcohol Abuse and Alcoholism. We could not trace those specific claims to the cited sources or a matching primary report, so we removed them. The studies below have separate identities and endpoints.

The animal finding is a starting point

In a 2013 rodent study, the GLP-1 receptor agonist exendin-4 reduced several alcohol-related behaviors in mice and rats, including alcohol seeking in a rat model. The investigators also measured alcohol-induced dopamine release in mice. This experiment did not study semaglutide users, human brain imaging, or treatment outcomes in people. It supports a research question about GLP-1 signaling, not a clinical benefit claim.

What the randomized human studies measured

  • A 2025 phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment to injected semaglutide or placebo. Semaglutide reduced alcohol consumed in the study’s primary laboratory self-administration task. Weekly craving and drinks per drinking day also fell relative to placebo, but average drinks per calendar day and the number of drinking days did not differ significantly. A laboratory task is not the same endpoint as long-term recovery.
  • A 2026 trial in The Lancet randomized 108 treatment-seeking adults with alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. After 26 weeks, the injected-semaglutide group had a greater reduction in the percentage of heavy-drinking days than the placebo group; the estimated between-group difference was −13.7 percentage points (95% CI −22.0 to −5.4). This result applies to the studied population and combined treatment setting.
  • A 2026 oral-semaglutide trial randomized 50 treatment-seeking adults with moderate to severe alcohol use disorder. Its primary laboratory measure of cue-elicited craving did not significantly improve versus placebo. Some secondary measures, including heavy-drinking days and craving reported outside the laboratory, favored semaglutide. Those secondary findings do not turn the negative primary result into a positive one.

These reports study semaglutide in different formulations, populations, durations, and settings. They cannot be presented as one experiment or as proof that every GLP-1 medicine reduces alcohol use. The article’s low evidence grade describes that broader claim, not a formal certainty assessment of every outcome in each trial.

A completed registration is not another published result

STAR-T (NCT05891587) is a separate phase 2 study with 80 participants enrolled. Its registry record said completed but showed no results posted when checked on 29 September 2026. Completion alone does not establish whether semaglutide helped its participants, and STAR-T should not be confused with any of the three published trials above.

The next questions concern which outcomes persist beyond short trials, whether the findings extend to people without the studied characteristics, and whether other GLP-1 medicines show similar effects. For the distinction between a compound’s evidence badge and a specific clinical claim, see the evidence-level reading guide.

This article explains research findings and their limits. It is not medical advice or a recommendation to use a medication for alcohol use disorder. People seeking help with alcohol use should speak with a qualified clinician.

Sources & Citations

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.